Insulin in type 2 diabetes: A useful alternative despite limited assessment based on surrogate endpoints

Prescrire International

Volumn 14, Issue 79, 2005, Pages 187-193

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; CORRELATION ANALYSIS; DIABETIC KETOACIDOSIS; DIABETIC MICROANGIOPATHY; DRUG EFFICACY; FLATULENCE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPEROSMOLARITY; HYPOGLYCEMIA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SODIUM RETENTION; STEROID THERAPY; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; WATER RETENTION; WEIGHT GAIN;

ACARBOSE; ADMINISTRATION, ORAL; CARBAMATES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; METFORMIN; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 27144502153     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. UK Prospective Diabetes Study (UKPDS) Group "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" Lancet 1998; 352: 837-853.
2. UK Prospective Diabetes Study (UKPDS) Group "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)" Lancet 1998; 352: 854-865.
3. Prescrire Editorial Staff "Treatment of type 2 diabetes" Prescrire Int 2003; 12 (63): 28-30.
4. De Witt DE, Hirsch IB "Outpatient insulin therapy in type 1 and type 2 diabetes mellitus" JAMA 2003; 289 (17): 2254-2264.
5. Prescrire Editorial Staff "Managing type 2 diabetes" Prescrire Int 2001; 10 (55): 158.
6. Stratton IM et al. "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study" BMJ 2000; 321: 405-412.
7. Bastyr EJ et al. "Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c" Diabetes Care 2000; 23 (9): 1236-1241.
8. Holman RR et al. "Sulphonylurea failure in type 2 diabetes: Treatment with a basal insulin supplement" Diabet Med 1987; 4: 457-462.
9. Klein W "Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients" Diabetes Metab 1991; 17: 235-240.
10. Trischitta V et al. "Comparison of combined therapies in treatment of secondary failure to glyburide" Diabetes Care 1992; 15 (4): 539-542.
11. Malone JK et al. "Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?" Diabetes Res Clin Pract 2003; 62 (3): 187-195.
12. Lopez-Alvarenga JC et al. "Acarbose vs bedtime NPH insulin in the treatment of secondary failures to sulfonylurea-metformin therapy in type 2 diabetes mellitus" Diabetes Obes Metab 1999; 1: 29-35.
13. Prescrire Editorial Staff "Pioglitazone, rosiglitazone. Glitazone + oral antidiabetics: inadequately evaluated" Prescrire Int 2005; 14 (78): 133-139.
14. Johnson JL et al. "Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes" Arch Intern Med 1996; 156: 259-264.
15. Feinglos MN et al. "Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus" Diabetes Res Clin Pract 1998; 39: 193-199.
16. Riddle MC et al. "Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone" Diabetes Care 1998; 21 (7): 1052-1057.
17. Wulffellé MG et al. "Combination of insulin and metformin in the treatment of type 2 diabetes" Diabetes Care 2002; 25 (12): 2133-2140.
18. Giugliano D et al. "Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors" Eur J Clin Pharmacol 1993; 44: 107-112.
19. Robinson AC et al. "The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control" Diabetes Care 1998; 21 (5): 701-705.
20. Avilés-Santa L et al. "Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial" Ann Intern Med 1999; 131: 182-188.
21. Fritsche A et al. "Intensive insulin therapy combined with metformin in obese type 2 diabetic patients" Acta Diabetol 2000; 37: 13-18.
22. Furlong NJ et al. "Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy" Diabetes Care 2002; 25 (10): 1685-1690.
23. Chiasson JL et al. "The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial" Ann Intern Med 1994; 121: 928-935.
24. Coniff RF et al. "A double-blind placebo controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type 2 diabetes" Diabetes Care 1995; 18 (7): 928-932.
25. Kelley DE et al. "Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes" Diabetes Care 1998; 21 (12): 2056-2061.
26. Holman RR et al. "A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK prospective diabetes study 44)" Diabetes Care 1999; 22 (6): 960-964.
27. Yki-Järvinen H "Combination therapies with insulin in type 2 diabetes" Diabetes Care 2001; 24 (4): 758-767.
28. Prescrire Editorial Staff "Rosiglitazone and pioglitazone" Prescrire Int 2002; 11 (62): 170-176.
29. Yki-Järvinen H et al. "Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial" Ann Intern Med 1999; 130 (5): 389-396.
30. Yki-Järvinen H et al. "Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus" N Engl J Med 1992; 327: 1426-1433.
31. Chow CC et al. "Comparison of insulin with or without continuations of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients" Diabetes Care 1995; 18 (3): 307-314.
32. Olsson PO et Lindström T "Combination-therapy with bedtime NPH insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes" Diabetes Metab 2002; 28 (4): 272-277.
33. Wolffenbuttel BHR et al. "Comparison of different insulin regimens in elderly patients with NIDDM" Diabetes Care 1996; 19 (12): 1326-1332.
34. Stehouwer MHA et al. "Combined bedtime insulin-daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on BbA1c and hypoglycaemia rate - a randomised trial" Diabetes Metab Res Rev 2003; 19: 148-152.
35. Clauson P et al. "Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up" Diabet Med 1996; 13: 471-477.
36. Bastyr EJ et al. "Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure" Clin Ther 1999; 21 (10): 1703-1714.
37. Janka HU et al. "Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes" Diabetes Care 2005; 28 (2): 254-259.
38. Goudswaard AN et al. "Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care" J Fam Pract 2004; 53 (5): 393-399.
39. van der Wal PS et al. "Efficacy of bedtime NPH insulin alone, as compared to combination with metformin and/or glipizide in NIDDM patients with secondary failure to oral hypoglycemic agents" Diabetes 1996; 45 (suppl. 2) (abstr. 1059): 286.
40. Furlong NJ et al. "Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with type 2 diabetes inadequately controlled with oral hypoglycaemic agents" Diabet Med 2003; 20 (11): 935-941.
41. Schiel R et al. "Quality of glycaemic control and well-being of patients with type 2 diabetes mellitus after switching from conventional insulin therapy to once daily insulin glargine in combination with oral antidiabetic drugs. SWITCH-pilot, a prospective, randomized trial" (abstr. 788), 18th congress of the International Diabetes Federation, Paris August 2003.
42. Yki-Järvinen H et al. "Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes" Diabetes Care 2000; 23 (8): 1130-1136.
43. Fritsche A et al. "Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial" Ann Intern Med 2003; 138 (12): 952-959.
44. Riddle MC et al. "The treat-to-target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients" Diabetes Care 2003; 26 (11): 3080-3086.
45. Raskin P et al. "Comparison of twice-daily biphasic insulin aspart 70/30 (NovoLog Mixo 70/30) with once-daily insulin glargine in patients with type 2 DM on oral antidiabetic agents" Presented at the 2004 conference of the American Diabetes Association, Orlando June 2004.
46. Goudswaard AN et al. "Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus" (Cochrane Review). In: "The Cochrane Library" John Wiley and Sons, Chichester 2005; Issue 1: 48 pages.